KYTHERA Biopharmaceuticals CEO Keith Leonard Sells 11,960 Shares (KYTH)
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith Leonard sold 11,960 shares of KYTHERA Biopharmaceuticals stock on the open market in a transaction dated Friday, November 1st. The shares were sold at an average price of $44.22, for a total transaction of $528,871.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on KYTH shares. Analysts at FBR & Co. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Separately, analysts at FBR Capital Markets initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating and a $58.00 price target on the stock. Finally, analysts at Bank of America Corp. initiated coverage on shares of KYTHERA Biopharmaceuticals in a research note to investors on Friday, October 25th. They set a “buy” rating on the stock. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $45.33.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 1.37% during mid-day trading on Monday, hitting $43.99. 93,141 shares of the company’s stock traded hands. KYTHERA Biopharmaceuticals has a 52-week low of $14.07 and a 52-week high of $47.85. The stock’s 50-day moving average is $43.79 and its 200-day moving average is $29.99. The company’s market cap is $934.7 million.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last released its earnings data on Tuesday, August 6th. The company reported ($0.67) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.70) by $0.03. On average, analysts predict that KYTHERA Biopharmaceuticals will post $-2.89 earnings per share for the current fiscal year.
KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.